SBIR/STTR Research Award
RENEWABLE CAPTURES FOR ADDICTION-RELEVANT PROTEINS
Award amount
$750,000Program and phase
SBIR · Phase IIAward year
2010Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AVANTGEN INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- WLNHKNPNT2M7
- Solicitation number
- PHS2010-1
- Topic code
- NIDA
Research abstract
The overall objective of the proposed scope of work for this Phase II contract is to leverage AvantGen's proprietary yeast display technology and synthetic human antibody library to isolate renewable capture agents against neuroscience proteins of interest in a more rapid, cost effective-manner. A successful outcome of this Phase II will generate panels of antibodies that are well suited for proteomics.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR FERRET BIOMARKERS.
- DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR INDIAN FLYING FOX (BAT) BIOMARKERS
- A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
- DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR FERRET BIOMARKERS
- DEVELOPMENT OF RAPID AND POINT-OF-CARE DIAGNOSTIC KIT FOR HEPATITIS C VIRUS DETECTION
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
24 SBIR/STTR records share this UEI (2008–2025). Reported award amounts total $14,979,724. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services